Formulary Watch |

All News - Page 9

Drug Costs, Regulation are Top of Mind of Mind for Employers
Drug Costs, Regulation are Top of Mind of Mind for Employers
Drug Costs, Regulation are Top of Mind of Mind for Employers
December 8, 2023
IQVIA’s Michael Kleinrock and experts at RxBenefits reveal during webinar top pharmacy trends going into 2024.
freshidea-stock.adobe.com
Study Questions Whether the High Price of Ocrevus is Warranted
Study Questions Whether the High Price of Ocrevus is Warranted
December 6, 2023
Researchers suggest a head-to-head comparative effectiveness study of Ocrevus and Rituxan/biosimilars in patients with multiple sclerosis is needed for payers to negotiate prices for these therapies.
Express Scripts and Cigna Add Zepbound to Formularies
Express Scripts and Cigna Add Zepbound to Formularies
Express Scripts and Cigna Add Zepbound to Formularies
December 5, 2023
Zepbound, which was approved last month to treat obesity, is now available in U.S. pharmacies.
 SpeedShutter_stock.adobe.com
IQVIA: Drug Shortages are Growing
IQVIA: Drug Shortages are Growing
December 4, 2023
Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.
Trifonenko Ivan-stock.adobe.com
Younger People Are Looking to GLP-1 Drugs for Weight Loss
Younger People Are Looking to GLP-1 Drugs for Weight Loss
November 30, 2023
A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.
HHS: Opportunities to Reduce Medicare Part B Spending with Biosimilars Remain
HHS: Opportunities to Reduce Medicare Part B Spending with Biosimilars Remain
HHS: Opportunities to Reduce Medicare Part B Spending with Biosimilars Remain
November 30, 2023
Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Analysis Finds Biosimilars Can Reduce Total Cost of Care
Analysis Finds Biosimilars Can Reduce Total Cost of Care
Analysis Finds Biosimilars Can Reduce Total Cost of Care
November 23, 2023
A simulation study estimated the impact of biosimilar substitution on total cost of care and provider financial performance in the final performance period of the Oncology Care Model.
CVS Caremark Switches Up Biosimilar Coverage in 2024
CVS Caremark Switches Up Biosimilar Coverage in 2024
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 20, 2023
New biosimilars have been added and others removed from CVS Caremark’s standard formulary. One notable change is with the Humira biosimilars. The PBM has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
© 2024 MJH Life Sciences

All rights reserved.